Yosemite’s rapid stride in biotech and AI
Team growth from inception to 17 members
When we last sat down with Reed Jobs at TechCrunch Disrupt nearly three years ago, his venture Yosemite was brand new and the biotech sector was still reeling from a post‑pandemic crash. Today, the firm has assembled a team of 17, a clear sign it is moving faster than anticipated.
Patent expirations create fresh opportunities
Jobs notes that “a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities.” The simultaneous loss of protection for multiple high‑revenue drugs opens a gap that emerging biotech firms can target with new formulations or follow‑on therapies.
AI shifts from curiosity to core capability
According to Jobs, AI has become “a huge part of what Yosemite does.” What began as a curiosity now underpins the firm’s scouting, evaluation, and investment processes, reflecting an industry‑wide push toward data‑driven decision‑making.
“I didn't expect Yosemite to be moving this fast,” he said.
Why it matters
Investors and founders: The patent cliff may spark a surge of venture‑backed biotech startups seeking to fill the void left by aging drugs.
AI integration: Yosemite’s deepening AI use signals that venture firms are leveraging machine learning to de‑risk biotech deals and accelerate deal flow.
Patients: Faster development of generics or novel therapies could improve access once the patent‑protected drugs exit the market.
What to watch next
Funding activity: Upcoming fundraising rounds could reveal how much capital is being allocated to AI‑enhanced biotech scouting.
Strategic partnerships: Alliances with AI‑focused labs or data platforms may amplify Yosemite’s ability to identify high‑potential targets.
Regulatory response: Keep an eye on how regulators address AI‑driven investment models in the biotech space.
Source: TechCrunch, “Reed Jobs would rather talk about curing cancer than his last name,” 12 Jul 2026.